Institute for Protein Design
Facts
- HQ
- University of Washington School of Medicine
- Sectors
- Biotechnology, Biopharma, Drug discovery, Protein engineering
Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline
Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.
Anindya Roy Co-founds Lila Biologics to Advance AI-Driven Medical Therapies After Journey from Rural India to UW Lab
Anindya Roy, who moved from rural India to the U.S. in 2008 with limited resources, has co-founded Lila Biologics in 2023 to develop innovative medical therapies using AI-powered protein design. His journey from humble beginnings to a postdoctoral fellowship under Nobel laureate David Baker exemplifies determination and scientific innovation.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
People
-
Chris Picardo Board Observer
-
David Baker Director
